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Harry Perkins Institute of Medical Research, QEII Medical Centre and Centre for Medical Research, The University of Western Australia, Nedlands, Western Australia, AustraliaThe Nkx factors are a family of homeodomain containing transcrip-
tion factors known to have tissue speciﬁc expression and thought to
play a regulatory role in organ development. Certain members of this
family have been studied in detail and found to play a role in disease.
For example, NKX6-1 is involved in pancreatic development and serves
as amarker for pancreatic and duodenal neuroendocrine tumors (Tseng
et al., 2015). Evidence also supports the role of NKX2-1 as an oncogene
in lung adenocarcinomas (Yamaguchi et al., 2013). These existing
examples as well as the suspected role of developmental processes in
cancer cell survival are grounds for further investigation into members
of this interesting transcription factor family.
Gastric cancer has one of the highest mortality rates of all cancers
(Stewart &Wild, 2014). Contributing to this, asymptomatic early stages
of the diseasemean patients often presentwith an advanced formof the
cancer. Once advanced, gastric cancer is often resistant to treatment and
the prognosis is poor. Furthermore, even where early stage treatment
has been possible, resurgence frequently occurs. Consequently, there
is clear motivation for understanding the molecular mechanisms of
disease progression.
The research presented in this issue of EBioMedicine by Yoon et al.
(2016) furthers our understanding of gastric cancer progression and
the role of Nkx factors with their investigation into NKX6, locus 3
(NKX6.3). NKX6.3 is the third member of the Nkx6 subfamily. It is nor-
mally expressed in the gastricmucosa and CNS (Alanentalo et al., 2006).
Previous studies by the same authors had found NKX6.3 expression
to be reduced in gastric cancers as a result of decreased DNA copy
number and allelic loss (Yoon et al., 2015). Building on these ﬁndings,
the present study correlates reduced NKX6.3 expression with more
severe measures of disease progression; higher tumor stage, lymph
node metastasis, and TNM (primary tumor, regional lymph node, and
metastasis) stage. Mining publically available data from the Gene
ExpressionOmnibus (GEO), demonstrated a strong correlation between
reduced expression of NKX6.3 and worse patient outcomes.
In dissecting the molecular basis for these important disease related
ﬁndings, Yoon et al. demonstrate the role of NKX6.3 in regulating
proteins involved in epithelial-mesenchymal transition (EMT). EMT is
important in wound healing, organ ﬁbrosis, and — of key relevanceDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.05.027.
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cer, particularly relating to cell motility and invasiveness (recently
reviewed by Huang et al. (2015)). Yoon et al. go on to demonstrate
NKX6.3 regulation of the Wnt/β-catenin signalling pathway as the
mechanism behind NKX6.3 mediated EMT. Expression proﬁles of
components of the Wnt/β-catenin signalling pathway are shown to be
controlled by NKX6.3 and their expression levels perturbed in gastric
cancer samples. This ﬁnding weaves the present study into a growing
body of research linking Wnt/β-catenin signalling to cancer develop-
ment and progression (Mohammed et al., 2016).
Yoon et al., also show NKX6.3 inhibits Rho-GTPase family proteins
which are known to contribute to cancer progression and development.
This is important as the Rho-GTPase family proteins RhoA and Rac1
have been shown to be up-regulated in gastric cancers (Pan et al.,
2004). This suggests reduced NKX6.3 mediates gastric cancer cell
migration and invasion though deregulation of Rho-GTPase family
proteins.
Placing this in the context of broader studies, analysis of gastric
cancers by The Cancer Genome Atlas Research Network discovered
four subtypes; microsatellite unstable tumors, genomically stable
tumors, Epstein-Barr virus, and tumors with chromosomal instability
(Bass et al., 2014). Interestingly, RHO-family GTPase-activating proteins
are implicated in the “genomically stable” tumor subtype. Future
studies could further explore whether NKX6.3 expression or biological
functions differ in each of these tumor subtypes.
In sum, the studies of Yoon et al. (2016) presented within this issue
build on a series of investigations and insights into NKX6.3 and the role
of EMT in gastric cancer. Given the prevalence and severity of gastric
cancer, the possible utility of NKX6.3 as a biomarker is promising.
Additionally, with further investigation there is also the potential to
explore treatments targeted at the control of NKX6.3.
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